HomeAI · summaries
Storia in 2 fonti
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway for front-line TNBC patients who are not candidates for PD-1/L1 inhibitors, the FDA has handed Gilead’s Trodelvy a rivaling approval that allows the drug to be used regardless of patients’ PD-L1 status.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
FDA grants Gilead two first-line approvals for Trodelvy in triple-negative breast cancer, broadening its reach beyond Datroway's narrower indication.
- ·
fiercepharma.com
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an approval for Daiichi Sankyo and AstraZeneca’s Datroway…